MENU
CRDF
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Cardiff Oncology (CRDF) Ownership - Who owns Cardiff Oncology?
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need... Show more
Profile
Industry
N/A
Address
11055 Flintkote Avenue
Phone
+1 858 952-7570
Employees
32
Web
https://www.cardiffoncology.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
202.9M
P/E Ratio
N/A
Total Cash
91.75M
Projected Growth
N/A
Total Debt
1.52M
Revenue
683K
Risk (Beta)
1.31
Dividend Yield
N/A
Total Cash/Share
1.38
Total Debt/Equity
N/A
Revenue/Share
0.01 USD as % of share price
Fundamentals
CRDF
Capitalization
203M
P/E Ratio
N/A
Risk (Beta)
1.31
Dividend Yield
N/A
Total Cash
91.7M
Total Cash/Share
1.38
Total Debt
1.52M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.01%
Revenue
683K
ROE
N/A
Book Value
82.9M
P/B Ratio
2.35
Cash Flow
N/A
Earnings
-0.95
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
7K
Current Ratio
7.08
Current Revenue Per Employee
4575.76
Dividends Per Share - Security
N/A
EBITDA
-48.25M
Float
N/A
Float - Current
N/A
Gross Income Margin
100.00
Revenue To Assets
-50.84
Shares Held By Institutions
144M
Shares Outstanding - Current
66.5M
Total Liabilities
14.2M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-32.604
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
11055 Flintkote Avenue
Phone
+1 858 952-7570
Employees
32
Web
https://www.cardiffoncology.com